MedDataX Logo

A Prospective, Observational, Multicentre, 2 Year Study Evaluating the Use of Eylea (Aflibercept) for the Treatment of Neovascular (Wet) Age-related Macular Degeneration in UK NHS Opthalmology Clinics

NCT ID: NCT02005133

Last Updated: 2017-02-28

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Total Enrollment

188 participants

Study Classification

OBSERVATIONAL

Study Start Date

2013-11-30

Study Completion Date

2015-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To assess the use of aflibercept over a 2 year period in VEGF inhibitor naive and prior treated wet AMD patients managed in 'real wold' clinic settings.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Prospective Observational Study to Assess Effectiveness of Intravitreal Aflibercept in Patients With Wet Macular Degeneration in Greece

NCT02821247

Choroidal Neovascularization Macular Degeneration
COMPLETED

Analysis of naïve Patients With Age-related Macular Degeneration of the Neovascular Type and Treated With Aflibercept (Eylea®) in "Treat-and-extend" at CHU Brugmann

NCT04891835

Age-related Macular Degeneration
COMPLETED

Aflibercept Injection Into the Vitreous Body of the Eye: Study to Learn More About Patient Relevant Outcomes, Real World Treatment Patterns and How Well the Treatment Works for Patients Suffering From Abnormal Growth of New Blood Vessels Under the Retina.

NCT03714308

Macular Degeneration
COMPLETED

Real Life of Aflibercept In FraNce: oBservatiOnnal Study in Wet AMD

NCT02279537

Wet Macular Degeneration
COMPLETED

Efficacy and Safety of the Aflibercept FYB203 Biosimilar in Comparison to Eylea® in Patients With Neovascular Age-Related Macular Degeneration

NCT04522167

Neovascular Age-related Macular Degeneration
COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Wet Age-related Macular Degeneration

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

VEGF inhibitor naïve

No interventions assigned to this group

VEGF inhibitor prior treated

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

\- Age greater or equal to 50 years Active choroidal neovascularisation secondary to AMD in one or both eyes which in the opinion of the investigator will benefit from treatment with aflibercept Subject willing and able to provide informed consent

Exclusion Criteria

\- Patients must not have had any prior use of either bevacizumab or aflibercept
Minimum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Novartis Pharmaceuticals

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Novartis Pharnmaceuticals

Role: STUDY_DIRECTOR

Novartis

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Novartis Investigative Site

Taunton, Somerset, United Kingdom

Site Status

Novartis Investigative Site

Frimley, Surrey, United Kingdom

Site Status

Novartis Investigative Site

London, United Kingdom, United Kingdom

Site Status

Novartis Investigative Site

Bradford, West Yorkshire, United Kingdom

Site Status

Novartis Investigative Site

Leeds, West Yorkshire, United Kingdom

Site Status

Novartis Investigative Site

Bolton, , United Kingdom

Site Status

Novartis Investigative Site

Bristol, , United Kingdom

Site Status

Novartis Investigative Site

Guildford, Surrey, , United Kingdom

Site Status

Novartis Investigative Site

Kent, , United Kingdom

Site Status

Novartis Investigative Site

Liverpool, , United Kingdom

Site Status

Novartis Investigative Site

London, , United Kingdom

Site Status

Novartis Investigative Site

Newcastle upon Tyne, , United Kingdom

Site Status

Novartis Investigative Site

Southampton, , United Kingdom

Site Status

Novartis Investigative Site

Southend, , United Kingdom

Site Status

Novartis Investigative Site

Sunderland, , United Kingdom

Site Status

Novartis Investigative Site

Uxbridge, , United Kingdom

Site Status

Novartis Investigative Site

York, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United Kingdom

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CRFB002AGB16

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Eylea to Treat Retinal Pigment Epithelial Detachment (RPED) Secondary to Wet Age-Related Macular Degeneration (wAMD)
NCT02142296 COMPLETED PHASE4
Aflibercept (EYLEA)as Secondary or Third Line Treatment for Neovascular Age-related Macular Degeneration.
NCT01918878 UNKNOWN PHASE4
Plasma Levels of Vascular Endothelial Growth Factor Before and After Intravitreal Injection of Aflibercept
NCT02125864 COMPLETED PHASE4
Managing Neovascular (Known as "Wet") Age-related Macular Degeneration Over 2 Years Using Different Treatment Schedules of 2 mg Intravitreal Aflibercept Injected in the Eye
NCT02581891 COMPLETED PHASE4
Aflibercept After Ranibizumab in Exudative Age-related Macular Degeneration
NCT02157077 COMPLETED PHASE3
An Integrated Analysis of the Effectiveness of Intravitreal (IVT) Aflibercept (Eylea) in Routine Clinical Practice Based on Two Large Observational Studies
NCT03521895 COMPLETED
A Study in Patients With Wet Age-related Macular Degeneration or Diabetic Macular Edema to Assess the freQuency of Use of Intravitreal Aflibercept in Routine Clinical Practices in Latin America
NCT03470103 COMPLETED
Assessment of Early Changes in SD-OCT After Initiation of a Treatment by Intravitreal Aflibercept (EYLEA®)START
NCT02246829 COMPLETED PHASE4
Evaluate the Effectiveness of Intravitreal (IVT) Aflibercept Injection in Clinical Practice in naïve Patients With Neovascular Age-related Macular Degeneration (nAMD)
NCT03411941 COMPLETED
Real-Life Clinical Outcomes of Aflibercept Biosimilar MY-1701P in the Treatment of Exudative Age-Related Macular Degeneration
NCT07235527 RECRUITING
A Study Reviewing Medical Records to Learn More About Treat-and-extend With Eylea in Patients With Neovascular Age-related Macular Degeneration (nAMD).
NCT04641234 COMPLETED
Effect Aflibercept on Ocular Perfusion
NCT03804099 COMPLETED PHASE4
Observational Study to Assess Intravitreal Aflibercept Injections Used in a "Treat and Extend" Regimen in Treatment-naïve Wet Age-related Macular Degeneration Patients
NCT03382587 COMPLETED
A Study to Learn How Well Aflibercept Injected Into the Eye Works and How Safe it is When Given in Customized Treatment Intervals in Patients With an Eye Disease Called Neovascular Age-related Macular Degeneration After Start of Treatment
NCT05473715 TERMINATED PHASE4
Aflibercept (Eylea) in roUtine Clinical Practice in patientS With Wet Age-related Macular Degeneration in Italy
NCT02289924 COMPLETED
Efficacy and Safety of Two Different Aflibercept Regimens in Subjects With Neovascular Age-related Macular Degeneration (nAMD)
NCT02540954 COMPLETED PHASE3
Structured Post-marketing Surveillance to Collect the Safety Data of Intravitreal Aflibercept Injection (IVT-AFL) in Patients of Wet Age-related Macular Degeneration During Real World Clinical Practice
NCT03290794 COMPLETED
Aflibercept in Polypoidal Choroidal Vasculopathy
NCT02120950 COMPLETED PHASE4
Clinical Study to Compare Efficacy and Safety of AVT06 and EU-Eylea (ALVOEYE)
NCT05155293 COMPLETED PHASE3
A Study to Understand Effectiveness and Safety of ABP 938 Compared to Aflibercept (Eylea®) in Patients Suffering With Neovascular Age-related Macular Degeneration [Neovascular (Wet) AMD]
NCT04270747 COMPLETED PHASE3
An Observational Study to Investigate the Use of Aflibercept 8 mg to Treat Adult Patients With Neovascular Age-Related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME) in a Real-World Setting
NCT06398080 WITHDRAWN
Investigating the Effectiveness of Eylea in Patients With Wet Age-related Macular Degeneration
NCT01914380 COMPLETED
Evaluation of Physician and Patient Knowledge of Safety and Safe Use Information for Aflibercept
NCT02615496 COMPLETED
Study of the Effects of High Dose Aflibercept Injected Into the Eye of Patients With an Age-related Disorder That Causes Loss of Vision Due to Growth of Abnormal Blood Vessels at the Back of the Eye
NCT04423718 COMPLETED PHASE3
A Study to Compare QL1207 to Eylea® in Subjects With Wet Age-related Macular Degeneration (wAMD)
NCT05345236 COMPLETED PHASE3